Amoy Diagnostics Co., Ltd. (SHE:300685)

China flag China · Delayed Price · Currency is CNY
23.71
+0.30 (1.28%)
Aug 1, 2025, 2:45 PM CST
1.28%
Market Cap9.18B
Revenue (ttm)1.15B
Net Income (ttm)300.04M
Shares Out386.86M
EPS (ttm)0.76
PE Ratio31.27
Forward PE28.94
Dividend0.30 (1.28%)
Ex-Dividend DateJun 3, 2025
Volume10,639,641
Average Volume10,673,330
Open23.90
Previous Close23.41
Day's Range23.41 - 24.03
52-Week Range17.47 - 28.79
Beta0.69
RSI60.52
Earnings DateJul 28, 2025

About ANSYS

Amoy Diagnostics Co., Ltd. engages in the development and commercialization of diagnostics product for oncology in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers, and advances targeted treatment research in ovarian cancer; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a CGP assay; AmoyDx BRCA Pro panel, covers various protein coding regions, intron/exon boundaries, sele... [Read more]

Sector Healthcare
Founded 2008
Employees 1,144
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300685
Full Company Profile

Financial Performance

In 2024, Amoy Diagnostics's revenue was 1.11 billion, an increase of 6.27% compared to the previous year's 1.04 billion. Earnings were 254.86 million, a decrease of -2.53%.

Financial Statements

News

There is no news available yet.